Literature DB >> 31501263

Hepatitis C Virus Structure: Defined by What It Is Not.

Altaira D Dearborn1,2, Joseph Marcotrigiano1.   

Abstract

Hepatitis C virus (HCV) represents an important and growing public health problem, chronically infecting an estimated 70 million people worldwide. This blood-borne pathogen is generating a new wave of infections in the United States, associated with increasing intravenous drug use over the last decade. In most cases, HCV establishes a chronic infection, sometimes causing cirrhosis, end-stage liver disease, and hepatocellular carcinoma. Although a curative therapy exists, it is extremely expensive and provides no barrier to reinfection; therefore, a vaccine is urgently needed. The virion is asymmetric and heterogeneous with the buoyancy and protein content similar to low-density lipoparticles. Core protein is unstructured, and of the two envelope glycoproteins, E1 and E2, the function of E1 remains enigmatic. E2 is responsible for specifically binding host receptors CD81 and scavenger receptor class B type I (SR-BI). This review will focus on structural progress on HCV virion, core protein, envelope glycoproteins, and specific host receptors.
Copyright © 2020 Cold Spring Harbor Laboratory Press; all rights reserved.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 31501263      PMCID: PMC6938659          DOI: 10.1101/cshperspect.a036822

Source DB:  PubMed          Journal:  Cold Spring Harb Perspect Med        ISSN: 2157-1422            Impact factor:   6.915


  77 in total

1.  Structure of dengue virus: implications for flavivirus organization, maturation, and fusion.

Authors:  Richard J Kuhn; Wei Zhang; Michael G Rossmann; Sergei V Pletnev; Jeroen Corver; Edith Lenches; Christopher T Jones; Suchetana Mukhopadhyay; Paul R Chipman; Ellen G Strauss; Timothy S Baker; James H Strauss
Journal:  Cell       Date:  2002-03-08       Impact factor: 41.582

2.  Unexpected mode of engagement between enterovirus 71 and its receptor SCARB2.

Authors:  Daming Zhou; Yuguang Zhao; Abhay Kotecha; Elizabeth E Fry; James T Kelly; Xiangxi Wang; Zihe Rao; David J Rowlands; Jingshan Ren; David I Stuart
Journal:  Nat Microbiol       Date:  2018-12-10       Impact factor: 17.745

3.  Mutations in hepatitis C virus p7 reduce both the egress and infectivity of assembled particles via impaired proton channel function.

Authors:  Matthew J Bentham; Toshana L Foster; Christopher McCormick; Stephen Griffin
Journal:  J Gen Virol       Date:  2013-08-01       Impact factor: 3.891

4.  Identification of amino acid residues in CD81 critical for interaction with hepatitis C virus envelope glycoprotein E2.

Authors:  A Higginbottom; E R Quinn; C C Kuo; M Flint; L H Wilson; E Bianchi; A Nicosia; P N Monk; J A McKeating; S Levy
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

5.  Binding of hepatitis C virus to CD81.

Authors:  P Pileri; Y Uematsu; S Campagnoli; G Galli; F Falugi; R Petracca; A J Weiner; M Houghton; D Rosa; G Grandi; S Abrignani
Journal:  Science       Date:  1998-10-30       Impact factor: 47.728

6.  The disulfide bonds in glycoprotein E2 of hepatitis C virus reveal the tertiary organization of the molecule.

Authors:  Thomas Krey; Jacques d'Alayer; Carlos M Kikuti; Aure Saulnier; Laurence Damier-Piolle; Isabelle Petitpas; Daniel X Johansson; Rajiv G Tawar; Bruno Baron; Bruno Robert; Patrick England; Mats A A Persson; Annette Martin; Félix A Rey
Journal:  PLoS Pathog       Date:  2010-02-19       Impact factor: 6.823

7.  Processing of hepatitis C virus core protein is regulated by its C-terminal sequence.

Authors:  Takanobu Kato; Michiko Miyamoto; Akihiro Furusaka; Tomoko Date; Kotaro Yasui; Junko Kato; Shozo Matsushima; Tatsuji Komatsu; Takaji Wakita
Journal:  J Med Virol       Date:  2003-03       Impact factor: 2.327

8.  Transmission of hepatitis C by blood splash into conjunctiva in a nurse.

Authors:  Salih Hosoglu; Mustafa Kemal Celen; Serife Akalin; Mehmet Faruk Geyik; Yasemin Soyoral; Ismail Hamdi Kara
Journal:  Am J Infect Control       Date:  2003-12       Impact factor: 2.918

9.  Complete replication of hepatitis C virus in cell culture.

Authors:  Brett D Lindenbach; Matthew J Evans; Andrew J Syder; Benno Wölk; Timothy L Tellinghuisen; Christopher C Liu; Toshiaki Maruyama; Richard O Hynes; Dennis R Burton; Jane A McKeating; Charles M Rice
Journal:  Science       Date:  2005-06-09       Impact factor: 47.728

10.  Receptor complementation and mutagenesis reveal SR-BI as an essential HCV entry factor and functionally imply its intra- and extra-cellular domains.

Authors:  Marlène Dreux; Viet Loan Dao Thi; Judith Fresquet; Maryse Guérin; Zélie Julia; Géraldine Verney; David Durantel; Fabien Zoulim; Dimitri Lavillette; François-Loïc Cosset; Birke Bartosch
Journal:  PLoS Pathog       Date:  2009-02-20       Impact factor: 6.823

View more
  4 in total

Review 1.  The role of MDM2-p53 axis dysfunction in the hepatocellular carcinoma transformation.

Authors:  Hui Cao; Xiaosong Chen; Zhijun Wang; Lei Wang; Qiang Xia; Wei Zhang
Journal:  Cell Death Discov       Date:  2020-06-19

Review 2.  The role of MDM2-p53 axis dysfunction in the hepatocellular carcinoma transformation.

Authors:  Hui Cao; Xiaosong Chen; Zhijun Wang; Lei Wang; Qiang Xia; Wei Zhang
Journal:  Cell Death Discov       Date:  2020-06-19

3.  An alternate conformation of HCV E2 neutralizing face as an additional vaccine target.

Authors:  Netanel Tzarum; Erick Giang; Rameshwar U Kadam; Fang Chen; Kenna Nagy; Elias H Augestad; Rodrigo Velázquez-Moctezuma; Zhen-Yong Keck; Yuanzi Hua; Robyn L Stanfield; Marlene Dreux; Jannick Prentoe; Steven K H Foung; Jens Bukh; Ian A Wilson; Mansun Law
Journal:  Sci Adv       Date:  2020-07-24       Impact factor: 14.136

4.  A conserved epitope III on hepatitis C virus E2 protein has alternate conformations facilitating cell binding or virus neutralization.

Authors:  Lu Deng; Nancy Hernandez; Lilin Zhong; David D Holcomb; Hailing Yan; Maria Luisa Virata; Sreya Tarafdar; Yanqun Xu; Yong He; Evi Struble; Harvey J Alter; Pei Zhang
Journal:  Proc Natl Acad Sci U S A       Date:  2021-07-13       Impact factor: 11.205

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.